vs
Arq, Inc.（ARQ）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Arq, Inc.的1.0倍（$30.3M vs $29.4M），REGENXBIO Inc.同比增速更快（43.0% vs 8.8%），Arq, Inc.自由现金流更多（$-3.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 16.4%）
Arq Inc是一家可持续发展技术企业，主营将煤矿开采废弃物加工为高价值低碳固体燃料及工业碳产品，服务能源、建筑、制造等领域客户，核心市场覆盖北美及欧洲主要地区，致力于帮助工业客户减少废弃物、降低碳排放。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ARQ vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$29.4M
营收增速更快
RGNX
高出34.2%
8.8%
自由现金流更多
ARQ
多$49.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
16.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.4M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | 13.6% | — |
| 营业利润率 | -174.1% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 8.8% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-1.20 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARQRGNX
| Q4 25 | $29.4M | $30.3M | ||
| Q3 25 | $35.1M | $29.7M | ||
| Q2 25 | $28.6M | $21.4M | ||
| Q1 25 | $27.2M | $89.0M | ||
| Q4 24 | $27.0M | $21.2M | ||
| Q3 24 | $34.8M | $24.2M | ||
| Q2 24 | $25.4M | $22.3M | ||
| Q1 24 | $21.7M | $15.6M |
净利润ARQRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-653.0K | $-61.9M | ||
| Q2 25 | $-2.1M | $-70.9M | ||
| Q1 25 | $203.0K | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $1.6M | $-59.6M | ||
| Q2 24 | $-2.0M | $-53.0M | ||
| Q1 24 | $-3.4M | $-63.3M |
毛利率ARQRGNX
| Q4 25 | 13.6% | — | ||
| Q3 25 | 28.8% | — | ||
| Q2 25 | 33.3% | — | ||
| Q1 25 | 36.4% | — | ||
| Q4 24 | 36.3% | 70.2% | ||
| Q3 24 | 38.6% | 48.8% | ||
| Q2 24 | 32.2% | 52.5% | ||
| Q1 24 | 36.9% | 72.6% |
营业利润率ARQRGNX
| Q4 25 | -174.1% | -190.0% | ||
| Q3 25 | -2.4% | -176.3% | ||
| Q2 25 | -5.4% | -296.3% | ||
| Q1 25 | 2.4% | 13.6% | ||
| Q4 24 | 1.5% | -242.1% | ||
| Q3 24 | 5.8% | -256.6% | ||
| Q2 24 | -5.6% | -251.3% | ||
| Q1 24 | -13.7% | -408.8% |
净利率ARQRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -1.9% | -208.3% | ||
| Q2 25 | -7.5% | -331.8% | ||
| Q1 25 | 0.7% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 4.7% | -246.3% | ||
| Q2 24 | -7.7% | -237.7% | ||
| Q1 24 | -15.7% | -405.4% |
每股收益（稀释后）ARQRGNX
| Q4 25 | $-1.20 | $-1.30 | ||
| Q3 25 | $-0.02 | $-1.20 | ||
| Q2 25 | $-0.05 | $-1.38 | ||
| Q1 25 | $0.00 | $0.12 | ||
| Q4 24 | $-0.03 | $-0.99 | ||
| Q3 24 | $0.04 | $-1.17 | ||
| Q2 24 | $-0.06 | $-1.05 | ||
| Q1 24 | $-0.09 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.6M | $230.1M |
| 总债务越低越好 | $28.7M | — |
| 股东权益账面价值 | $168.0M | $102.7M |
| 总资产 | $230.6M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资ARQRGNX
| Q4 25 | $6.6M | $230.1M | ||
| Q3 25 | $7.0M | $274.2M | ||
| Q2 25 | $7.0M | $323.3M | ||
| Q1 25 | $6.3M | $267.9M | ||
| Q4 24 | $13.5M | $234.7M | ||
| Q3 24 | $48.7M | $255.5M | ||
| Q2 24 | $28.5M | $290.4M | ||
| Q1 24 | $35.2M | $338.7M |
总债务ARQRGNX
| Q4 25 | $28.7M | — | ||
| Q3 25 | $26.1M | — | ||
| Q2 25 | $28.9M | — | ||
| Q1 25 | $27.1M | — | ||
| Q4 24 | $25.1M | — | ||
| Q3 24 | $21.6M | — | ||
| Q2 24 | $22.2M | — | ||
| Q1 24 | $22.6M | — |
股东权益ARQRGNX
| Q4 25 | $168.0M | $102.7M | ||
| Q3 25 | $217.2M | $161.5M | ||
| Q2 25 | $216.8M | $213.7M | ||
| Q1 25 | $218.2M | $274.2M | ||
| Q4 24 | $217.3M | $259.7M | ||
| Q3 24 | $218.1M | $301.4M | ||
| Q2 24 | $189.6M | $348.3M | ||
| Q1 24 | $175.2M | $390.7M |
总资产ARQRGNX
| Q4 25 | $230.6M | $453.0M | ||
| Q3 25 | $277.9M | $525.2M | ||
| Q2 25 | $284.5M | $581.0M | ||
| Q1 25 | $283.7M | $490.9M | ||
| Q4 24 | $284.4M | $466.0M | ||
| Q3 24 | $280.0M | $519.1M | ||
| Q2 24 | $248.6M | $569.4M | ||
| Q1 24 | $229.8M | $629.2M |
负债/权益比ARQRGNX
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.12× | — | ||
| Q1 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-3.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | -12.0% | -174.0% |
| 资本支出强度资本支出/营收 | 2.7% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-11.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ARQRGNX
| Q4 25 | $-2.8M | $-52.3M | ||
| Q3 25 | $5.3M | $-56.0M | ||
| Q2 25 | $527.0K | $-49.3M | ||
| Q1 25 | $-5.8M | $33.6M | ||
| Q4 24 | $5.2M | $-31.6M | ||
| Q3 24 | $7.7M | $-40.5M | ||
| Q2 24 | $-3.0M | $-45.5M | ||
| Q1 24 | $526.0K | $-55.5M |
自由现金流ARQRGNX
| Q4 25 | $-3.5M | $-52.8M | ||
| Q3 25 | $3.1M | $-56.5M | ||
| Q2 25 | $-1.4M | $-49.7M | ||
| Q1 25 | $-9.5M | $32.6M | ||
| Q4 24 | $-37.8M | $-32.7M | ||
| Q3 24 | $-5.8M | $-40.9M | ||
| Q2 24 | $-22.1M | $-46.0M | ||
| Q1 24 | $-9.1M | $-56.0M |
自由现金流率ARQRGNX
| Q4 25 | -12.0% | -174.0% | ||
| Q3 25 | 8.8% | -189.9% | ||
| Q2 25 | -4.7% | -232.8% | ||
| Q1 25 | -34.9% | 36.6% | ||
| Q4 24 | -139.6% | -154.2% | ||
| Q3 24 | -16.5% | -168.9% | ||
| Q2 24 | -87.1% | -206.2% | ||
| Q1 24 | -41.7% | -358.5% |
资本支出强度ARQRGNX
| Q4 25 | 2.7% | 1.7% | ||
| Q3 25 | 6.3% | 1.7% | ||
| Q2 25 | 6.6% | 1.8% | ||
| Q1 25 | 13.6% | 1.2% | ||
| Q4 24 | 158.9% | 5.1% | ||
| Q3 24 | 38.7% | 1.3% | ||
| Q2 24 | 75.5% | 2.1% | ||
| Q1 24 | 44.1% | 3.6% |
现金转化率ARQRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -28.59× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARQ
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
